**ROLE SUMMARY** The US Prostate Cancer Business is one of the largest and fastest growing franchises within Pfizer. It is anchored by a multibillion dollar asset (XTANDI), a growth brand (ORGOVYX), and a recently launched TALZENNA in combination with XTANDI in Prostate Cancer. TALZENNA in prostate has the potential to deliver over $1.5B in peak […]